International Journal of Cancer Management

Published by: Kowsar

Applying Bioinformatic Tools for Modeling and Modifying Type II E. coli l-Asparginase to Present a Better Therapeutic Agent/Drug for Acute Lymphoblastic Leukemia

Mahdieh Mahboobi 1 , 2 , Hamid Sedighian 1 , Mojtaba Hedayati CH 3 , Bijan Bambai 2 , Saeed Esmaeil Soofian 4 and Jafar Amani 1 , *
Authors Information
1 Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 Department of Systems Biotechnology, National Institute for Genetic Engineering and Biotechnology (NIGEB), Tehran, IR Iran
3 Department of Microbiology, Parasitology and Immunology, Guilan University of Medical Sciences, Rasht, Guilan, IR Iran
4 Department of Internal Medicine Faculty of Medicine, Iran University of Medical Sciences, Tehran, IR Iran
Article information
  • International Journal of Cancer Management: March 2017, 10 (3); e5785
  • Published Online: March 20, 2017
  • Article Type: Research Article
  • Received: February 23, 2016
  • Revised: June 7, 2016
  • Accepted: March 7, 2017
  • DOI: 10.5812/ijcm.5785

To Cite: Mahboobi M, Sedighian H, Hedayati CH M, Bambai B, Esmaeil Soofian S, et al. Applying Bioinformatic Tools for Modeling and Modifying Type II E. coli l-Asparginase to Present a Better Therapeutic Agent/Drug for Acute Lymphoblastic Leukemia, Int J Cancer Manag. 2017 ; 10(3):e5785. doi: 10.5812/ijcm.5785.

Abstract
Copyright © 2017, International Journal of Cancer Management. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Methods
3. Results
4. Discussion
Footnotes
References
  • 1. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998; 339(9): 605-15[DOI][PubMed]
  • 2. McEntee M, Silverman JA, Rassnick K, Zgola M, Chan AO, Tau PT, et al. Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. Vet Comp Oncol. 2003; 1(2): 105-12[DOI][PubMed]
  • 3. Rahbar MR, Rasooli I, Mousavi Gargari SL, Amani J, Fattahian Y. In silico analysis of antibody triggering biofilm associated protein in Acinetobacter baumannii. J Theor Biol. 2010; 266(2): 275-90[DOI][PubMed]
  • 4. Swain AL, Jaskolski M, Housset D, Rao JK, Wlodawer A. Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy. Proc Natl Acad Sci U S A. 1993; 90(4): 1474-8[PubMed]
  • 5. Cooney DA, Handschumacher RE. L-asparaginase and L-asparagine metabolism. Annu Rev Pharmacol. 1970; 10: 421-40[DOI][PubMed]
  • 6. Whitecar JJ, Bodey GP, Hill CJ, Samaan NA. Effect of L-asparaginase on carbohydrate metabolism. Metabolism. 1970; 19(8): 581-6[PubMed]
  • 7. Yun MK, Nourse A, White SW, Rock CO, Heath RJ. Crystal structure and allosteric regulation of the cytoplasmic Escherichia coli L-asparaginase I. J Mol Biol. 2007; 369(3): 794-811[DOI][PubMed]
  • 8. Haskell CM, Canellos GP, Leventhal BG, Carbone PP, Block JB, Serpick AA, et al. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med. 1969; 281(19): 1028-34[DOI][PubMed]
  • 9. Capizzi RL. Asparaginase revisited. Leuk Lymphoma. 1993; 10 Suppl: 147-50[DOI][PubMed]
  • 10. Li LZ, Xie TH, Li HJ, Qing C, Zhang GM, Sun MS. Enhancing the thermostability of Escherichia coli l-asparaginase II by substitution with pro in predicted hydrogen-bonded turn structures. Enzyme Microb Technol. 2007; 41(4): 523-7[DOI]
  • 11. Luscombe NM, Greenbaum D, Gerstein M. What is bioinformatics? An introduction and overview. Yearb Med Inform. 2001; (1): 83-99[PubMed]
  • 12. Blundell TL, Sibanda BL, Montalvao RW, Brewerton S, Chelliah V, Worth CL, et al. Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery. Philos Trans R Soc Lond B Biol Sci. 2006; 361(1467): 413-23[DOI][PubMed]
  • 13. Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, Chetvernin V, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2007; 35-12[DOI][PubMed]
  • 14. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 2003; 31(13): 3497-500[PubMed]
  • 15. Bairoch A, Apweiler R, Wu CH, Barker WC, Boeckmann B, Ferro S, et al. The Universal Protein Resource (UniProt). Nucleic Acids Res. 2005; 33-9[DOI][PubMed]
  • 16. Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Open Source Drug Discovery C, et al. In silico approach for predicting toxicity of peptides and proteins. PLoS One. 2013; 8(9)[DOI][PubMed]
  • 17. Gilis D, Rooman M. PoPMuSiC, an algorithm for predicting protein mutant stability changes: application to prion proteins. Protein Eng. 2000; 13(12): 849-56[PubMed]
  • 18. Garnier J, Gibrat JF, Robson B. GOR method for predicting protein secondary structure from amino acid sequence. 1996; [DOI]
  • 19. Du H, Brender JR, Zhang J, Zhang Y. Protein structure prediction provides comparable performance to crystallographic structures in docking-based virtual screening. Methods. 2015; 71: 77-84[DOI][PubMed]
  • 20. Bridge A, Lane L, Stockinger H, Appel R, Xenarios I. Databases and Datasources at SIB, Swiss Institute of Bioinformatics. 2014; [DOI]
  • 21. Mohabatkar H, Kar SK. Prediction of exposed domains of envelope glycoprotein in Indian HIV-1 isolates and experimental confirmation of their immunogenicity in humans. Braz J Med Biol Res. 2004; 37(5): 675-81[PubMed]
  • 22. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007; 8: 4[DOI][PubMed]
  • 23. Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA, et al. The biology of IGE and the basis of allergic disease. Annu Rev Immunol. 2003; 21: 579-628[DOI][PubMed]
  • 24. Saha S, Raghava GP. AlgPred: prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res. 2006; 34-9[DOI][PubMed]
  • 25. Rodrigues JP, Levitt M, Chopra G. KoBaMIN: a knowledge-based minimization web server for protein structure refinement. Nucleic Acids Res. 2012; 40-8[DOI][PubMed]
  • 26. El-Manzalawy Y, Dobbs D, Honavar V. Predicting linear B-cell epitopes using string kernels. J Mol Recognit. 2008; 21(4): 243-55[DOI][PubMed]
  • 27. Kringelum JV, Lundegaard C, Lund O, Nielsen M. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput Biol. 2012; 8(12)[DOI][PubMed]
  • 28. Cho A, Seife C, Lawler A, Leggett A, Dunningham J, Rau A. Robert Coontz, Ian Osborne, and Phil Szuromi Science. Science. 2005; 11: 865
  • 29. De Groot AS, Berzofsky JA. From genome to vaccine--new immunoinformatics tools for vaccine design. Methods. 2004; 34(4): 425-8[DOI][PubMed]
  • 30. Barnes WR, Vela GR, Dorn GL. Physiology of L-asparaginase synthesis in recombinants of Escherichia coli A-1. Appl Environ Microbiol. 1978; 35(4): 766-70[PubMed]
  • 31. Aghaeepoor M, Mozafari S, Shahraki MK, Tabandeh F, Bambai B. High level of extracellular fermentation and alternative purification of Escherichia coli asparaginase II. Biharean Biol. 2011; 5(2): 96-101
  • 32. Guo QL, Wu MS, Chen Z. Comparison of antitumor effect of recombinant L-asparaginase with wild type one in vitro and in vivo. Acta Pharmacol Sin. 2002; 23(10): 946-51[PubMed]
  • 33. Vrooman LM, Kirov ,I, Dreyer ZE, Kelly M, Hijiya N, Brown P, et al. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia. Pediatr Blood Cancer. 2016; 63(2): 228-33[DOI][PubMed]
  • 34. Yoshimoto T, Nishimura H, Saito Y, Sakurai K, Kamisaki Y, Wada H, et al. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia. Jpn J Cancer Res. 1986; 77(12): 1264-70[PubMed]
  • 35. Hernandez CP, Morrow K, Lopez-Barcons LA, Zabaleta J, Sierra R, Velasco C, et al. Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood. 2010; 115(25): 5214-21[DOI][PubMed]
  • 36. Fu CH, Sakamoto KM. PEG-asparaginase. Expert Opin Pharmacother. 2007; 8(12): 1977-84[DOI][PubMed]
  • 37. Soares AL, Guimaraes GM, Polakiewicz B, de Moraes Pitombo RN, Abrahao-Neto J. Effects of polyethylene glycol attachment on physicochemical and biological stability of E. coli L-asparaginase. Int J Pharm. 2002; 237(1-2): 163-70[PubMed]
  • 38. Alrazzak M, Beaupin LK, Kinyoun P, Barth M. The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience. J Pediatr Hematol Oncol. 2016; 38(1)-20[DOI][PubMed]
  • 39. Cabrita LD, Gilis D, Robertson AL, Dehouck Y, Rooman M, Bottomley SP. Enhancing the stability and solubility of TEV protease using in silico design. Protein Sci. 2007; 16(11): 2360-7[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments